Lupin gets USFDA nod for generic potassium chloride oral solution

PTI New Delhi | Updated on August 31, 2018 Published on August 31, 2018

Shares of Lupin were trading up by 3.6 per cent at Rs 762.90 on the BSE.

Drug firm Lupin today said it has received approval from the US health regulator to sell its potassium chloride oral solution used for the treatment of low potassium levels in the American market.

The company has received approval to market its potassium chloride oral solution USP, in the strengths of 20 mEq/15 ml (10 per cent) and 40 mEq/15 ml (20 per cent) from the United States Food and Drug Administration (USFDA), Lupin said in a filing to BSE.

The company’s product is a generic version of Genus Lifesciences Inc’s potassium chloride oral solution in the same strengths, it added. According to IQVIA MAT June 2018 data the oral solution in the two strengths had annual sales of around $184.95 million in the US, Lupin said.

“The product is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods and/or diuretic dose reduction are insufficient,” it added.

Shares of Lupin Ltd were trading at Rs 933.35 on BSE, up 4.44 per cent from the previous close.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on August 31, 2018
This article is closed for comments.
Please Email the Editor